1. Enhancement of anti-tumor immunity and survival prolongation by neoadjuvant 5-FU, oxaliplatin and irinotecan (folfirinox) in pancreatic ductal adenocarcinoma patients. (March 2018) Authors: Cai, L.; Michelakos, T.; Castillo, C.F.; Yamada, T.; Taylor, M.S.; Deshpande, V.; Qadan, M.; Allen, J.; Clark, J.W.; Hong, T.S.; Ryan, D.P.; Wo, J.Y.; Warshaw, A.L.; Lillemoe, K.D.; Ferrone, S.; Ferrone, C.R. Journal: HPB Issue: Volume 20(2018)Supplement 1 Page Start: S10 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗